Jon McClellan
It is Standard Practice to prescribe neuroleptic and other psychiatric drugs that have not been tested for safety and/or efficacy in children and adolescents because the Treatment Protocols and Practice Parameters and algorithms written by Jon McClellan and others, recommend using the drugs for children's behavioral problems and for virtually every psychiatric diagnosis given to children and teens.What really gets me is this 'doctor' is considered a lead researcher and 'an authority' who actually helped write the book, so to speak, on using psychiatric drugs on kids, but claimed in a Senate Hearing he has no insight into why it is actually being done!?! Jon McClellan's failure to comply with or conform to Ethical Guidelines and Legal Standards when he 'treated' my son, should have cost him his license to practice medicine. This 'doctor,' as an agent working for the State of Washington, violated every single Ethical and Legal parameter applicable to the practice of medicine and bio-medical research involving human subjects and used my son like a lab animal without regard to his human dignity; without proper consent, and over my vehement protests. This 'doctor' claimed in a Senate Hearing to have no insight into how teratogenic drugs he recommends and advises other professionals how to use, came to be in widespread use; despite the lack of valid safety or efficacy data to validate or support this 'Standard Practice.'
Jon McClellan's callous disregard for the deleterious effects of the drugs on my son was horrifying for a mother to witness; his utter lack empathy and compassion were devastating, as was the lack of accountability or responsibility for further traumatizing and ultimately disabling my once brilliant son.
Jon McClellan has ample experience prescribing psychotropic drugs off-label over the last couple of decades. He has taught students at the University of Washington, and advises other medical professionals in phone consultations in a program that Washington State implemented. In spite of these facts, and a professional career over 2 + decades, he claims to have no insight whatsoever into the prescribing practices he uses and recommends to others. Prescribing practices which have defrauded taxpayers through the Medicaid program. Worse than the decimated budgets and robbing of the American taxpayers, is the plight of the primary victims of this psychiatric practice: the children whose lives have been forever altered, like my son's has been; and the children whose lives have been lost: like Rebecca Riley and Gabriel Meyers.
Does anyone really believe Jon McClellan has absolutely no insight into the reason this investigation is needed? Does anybody wonder what happens to doctors who prescribe drugs off-label, and ultimately cause a child's death? The "doctor" that "treated" Gabriel Meyer to death, got a "warning letter" and still has a medical license to practice medicine. The "doctor" that "treated" Rebecca Riley to death was granted immunity for testifying against her mother at trial. As usual, Jon McClellan was quoted in the press when these events occurred: This expert who claims he has NO IDEA why these drugs are being used so widely, with such ill effects, without being first tested or approved as safe and/or efficacious for pediatric use, on thousands of children across the Country----always has something to say about the drugs when they kill children. But, strangely, he testified in a Senate hearing, he has NO IDEA why prescribing the drugs as he himself recommends is Standard Practice...
Jon McClellan's claim that he doesn't know why dangerous, teratogenic drugs are so widely used in the pediatric population, begs the question: "Why do the numerous Practice Parameters Jon McClellan wrote or helped develop for the American Academy of Child and Adolescent Psychiatry recommend using neuroleptic and other psychotropic drugs both on- and off-label for the pediatric population and what exactly are this psychiatrist's recommendations based on?"
via ACCAP:
PRACTICE PARAMETER FOR THE ASSESSMENT AND TREATMENT OF
CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA
PRACTICE PARAMETER FOR THE USE OF ATYPICAL ANTIPSYCHOTIC
MEDICATIONS IN CHILDREN AND ADOLESCENTS
This parameter was reviewed at the Member Forum at the AACAP Annual Meeting in
October 2006.
From January 2008 to October 2008 and from November 2010 to June 2011, this
parameter was reviewed by a Consensus Group convened by the CQI. Consensus Group
members and their constituent groups were as follows: CQI (Oscar Bukstein, M.D., chair and
shepherd; Allan Chrisman, M.D., John Hamilton, M.D., and Matthew Siegel, M.D., members);
Topic Experts (Jon McClellan, M.D. and Christopher McDougle, M.D.); AACAP Assembly of
Regional Organizations (Sherry Barron-Seabrook, M.D. and Gail Edelsohn, M.D.); and AACAP
Council (David R. DeMaso, M.D. and Melvin Oatis, M.D.).
This practice parameter was approved by the AACAP Council on August 2, 2011 here
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder
Accepted August 15, 2006.
This parameter was developed by Jon McClellan, M.D., Robert Kowatch, M.D.,
Robert L. Findling, M.D.,
This parameter was reviewed at the member forum in October 2004 at the
annual meeting of the American Academy of Child and Adolescent Psychiatry.
During August 2005, a consensus group reviewed and finalized the content of
this practice parameter. The consensus group consisted of representatives of relevant
AACAP components as well as independent experts: Oscar Bukstein, M.D., Work
Group Co-Chair; Jon McClellan, M.D., author here
Summary of the Practice Parameters for the Assessment and Treatment of Children and Adolescents with Depressive Disorders
Principal Authors: Boris Birmaher, M.D., David A. Brent, M.D., and R. Scott Benson, M.D. This Summary was developed by the Work Group on Quality Issues: William Bernet, M.D., Chair, and John E. Dunne, M.D., former Chair, Maureen Adair, M.D., Valerie Arnold, M.D., R. Scott Benson, M.D., Oscar Bukstein, M.D., Joan Kinlan, M.D., Jon McClellan, M.D., and David Rue, M.D. here
Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults
via MedScape Education:
Use of Antipsychotic Medication in Children and Adolescents here by Jon McClellan 2009
Faculty and Disclosures
As an organization accredited by the ACCME, MedscapeCME requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
MedscapeCME encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
0 comments:
Post a Comment